Jerald P. Radich
Fred Hutchinson Cancer Center
Public scientific profile · Unclaimed
Built from public scholarly sources. Expertise is inferred by ScienceWe from publications and has not been confirmed by the scientist.
Top expertise
Acute Myeloid Leukemia Research
Strong evidence · 13 supporting papers · latest 2026
Chronic Myeloid Leukemia Treatments
Strong evidence · 10 supporting papers · latest 2026
Epigenetics and DNA Methylation
Solid evidence · 1 supporting paper · latest 2026
Myeloproliferative Neoplasms: Diagnosis and Treatment
Solid evidence · 4 supporting papers · latest 2026
Hematopoietic Stem Cell Transplantation
Solid evidence · 2 supporting papers · latest 2026
Acute Lymphoblastic Leukemia research
Solid evidence · 3 supporting papers · latest 2026
Multiple Myeloma Research and Treatments
Solid evidence · 2 supporting papers · latest 2025
Protein Degradation and Inhibitors
Solid evidence · 2 supporting papers · latest 2025
Publications (15)
Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML
2026DOIPMID 41282928
Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium
2025DOI
Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report
2025DOI
Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia
2025DOIPMID 41286512
Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission
2025DOI
Improving karyotype success for myelomatch: Evidence-based culturing optimization for rapid AML screening - an NCI myelomatch and SWOG report
2025DOI
Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch
2025DOI
Differential Gene Expression during Conditioning Correlates with Outcomes in Allotransplant Recipients with AML and MDS
2026DOI
Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report
2025DOI
Introduction to the Review Series. Chronic myeloid leukemia in 2026
2026DOIPMID 42383666
Genome-Wide Epigenetic Comparisons in Long-Term Donor-Recipient Pairs Decades after Allogeneic Hematopoietic Cell Transplantation
2026DOI
Predictive biomarkers of sustained treatment-free remission in chronic myeloid leukemia: gene expression analyses from the ENESTfreedom and ENESTop studies
2026DOIPMID 41885027
Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.
2025DOI
A Framework for Locally Imputing and Predicting Biomarker Trajectories Under Irregular Monitoring: Application to Chronic Myeloid Leukemia
2026DOIPMID 41542066
A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)
2026DOIPMID 41646009
Organizations in sourced records
Affiliation evidence only — not confirmed current employment.
- Fred Hutchinson Cancer Center
Source: OpenAlex · retrieved 2026-09-29
Source: ScienceWe Extractor · retrieved 2026-09-27